Finance

Beta
Lists
600211:SHA
Tibet Rhodiola Pharmaceutical Holding Co
CNÂ¥37.62
0.00%
(0.00) 1D
Jun 5, 3:00:04 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 600211...
Open
CNÂ¥37.90
High
CNÂ¥38.01
Low
CNÂ¥37.51
Mkt. cap
12.13B
Avg. vol.
3.23M
Volume
2.01M
Dividend
4.67%
Quarterly dividend
CNÂ¥0.44
Ex-dividend date
May 22, 2026
P/E ratio
12.53
52-wk high
CNÂ¥57.98
52-wk low
CNÂ¥35.60
EPS
CNÂ¥3.00
Shares outstanding
179.62M
No. of employees
671
Open
CNÂ¥37.90
High
CNÂ¥38.01
Low
CNÂ¥37.51
Mkt. cap
12.13B
Avg. vol.
3.23M
Volume
2.01M
Dividend
4.67%
Quarterly dividend
CNÂ¥0.44
Ex-dividend date
May 22, 2026
P/E ratio
12.53
52-wk high
CNÂ¥57.98
52-wk low
CNÂ¥35.60
EPS
CNÂ¥3.00
Shares outstanding
179.62M
No. of employees
671
News stories
From sources across the web
About Tibet Rhodiola Pharmaceutical Holding Co
CEO-
Employees671
FoundedJul 14, 1999
Headquarters-
SectorHealth care provider
Websitexzyy.cn
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
938.60M
438.57M
892.27M
723.55M
Cost of goods sold
52.39M
41.19M
41.01M
51.38M
Cost of revenue
52.39M
41.19M
41.01M
51.38M
Research and development expenses
13.50M
9.35M
45.96M
26.48M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
541.93M
248.18M
569.90M
425.75M
Operating expense
570.96M
218.72M
669.38M
457.07M
Total operating expenses
623.35M
259.91M
710.39M
508.44M
Operating income
315.24M
178.66M
181.87M
215.11M
Other non operating income
-2.86M
1.73M
-1.78M
150.65K
EBT including unusual items
335.67M
173.13M
230.16M
316.64M
EBT excluding unusual items
328.77M
191.14M
188.37M
224.35M
Income tax expense
35.13M
18.02M
39.09M
33.80M
Effective tax rate
10.47%
10.41%
16.98%
10.68%
Other operating expenses
14.74M
-38.78M
54.69M
4.84M
Net income
298.04M
154.45M
216.15M
298.71M
Net profit margin
31.75%
35.22%
24.23%
41.28%
Earnings per share
-
-
-
-
Interest and investment income
14.48M
14.86M
17.37M
19.24M
Interest expense
-148.31K
-2.04M
-10.40M
-10.15M
Net interest expenses
14.33M
12.82M
6.97M
9.09M
Depreciation and amortization charges
-
-
-
-
EBITDA
333.34M
197.21M
201.24M
234.47M
Gain or loss from assets sale
-152.70K
152.70K
-108.68K
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer